Agentix Corp. is a clinical-stage biotechnology company that is dedicated to the development of therapies for metabolic diseases, including type 2 diabetes (T2D), obesity, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
There is a need for more treatments as the manifestations of metabolic disease continue to be prevalent in the USA. According to the CDC, over 30 million Americans have T2D1 and approximately 100 million US adults are obese2. Furthermore, an estimated 64 million US adults have NAFLD3. Of those with obesity, over 9% of cases are considered to be severe while it is predicted that 20% of NAFLD cases will progress to NASH.